The FDA Thursday issued a draft guidance, Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination, that should ease the regulatory burden of developing a companion diagnostic for use with an investigational cancer drug or biological product.